Synmosa Biopharma (4114.TWO) Earnings Analysis

Synmosa Biopharma (4114.TWO) next reports earnings on 2026-08-18, consensus EPS 0.4075 TWD. Last quarter (2026-03-26) it missed with EPS 0.38 TWD vs 0.584 TWD est (-34.9%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E 18.69.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4114.TWO next report earnings?

Next earnings date2026-08-18
Consensus EPS estimate0.4075 TWD
Revenue estimate1.68B

4114.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-260.38 TWD0.584 TWD-34.9%Miss
2025-03-060.32 TWD0.4772 TWD-32.9%Miss
2024-11-140.39 TWD0.519 TWD-24.9%Miss
2024-08-050.4438 TWD0.4438 TWD0%Beat

Beat rate: 1/4 (25%) over reported quarters with consensus data.

4114.TWO valuation and analyst view

Trailing P/E18.69
Trailing EPS1.509 TWD
Price / book1.67
Dividend yield2.89%
Market cap15.97B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Synmosa Biopharma (4114.TWO)'s next earnings date?

Synmosa Biopharma is next scheduled to report on 2026-08-18, with a consensus EPS estimate of 0.4075 TWD and revenue estimate of 1.68B.

Did 4114.TWO beat earnings last quarter?

In its 2026-03-26 report, 4114.TWO posted EPS of 0.38 TWD versus a 0.584 TWD estimate — a miss of 34.9%.

What is 4114.TWO's earnings track record?

Over the last 4 reported quarters with consensus data, 4114.TWO beat estimates 1 times (25%).

What is 4114.TWO's current P/E ratio and EPS?

4114.TWO trades at a trailing P/E of 18.69 on trailing EPS of 1.5090840060746542 TWD.

What do analysts rate 4114.TWO?

4114.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.